Three-dimensional Modeling of and Ligand Docking to Vitamin D Receptor Ligand Binding Domain

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2000 Mar 4

PMID 10677485

Citations 10

Authors

K Yamamoto

H Masuno

M Choi

K Nakashima

T Taga

H Ooizumi

K Umesono

W Sicinska

J VanHooke

H F DeLuca

S Yamada

Affiliations

Soon will be listed here.

Abstract

The ligand binding domain of the human vitamin D receptor (VDR) was modeled based on the crystal structure of the retinoic acid receptor. The ligand binding pocket of our VDR model is spacious at the helix 11 site and confined at the beta-turn site. The ligand 1alpha, 25-dihydroxyvitamin D(3) was assumed to be anchored in the ligand binding pocket with its side chain heading to helix 11 (site 2) and the A-ring toward the beta-turn (site 1). Three residues forming hydrogen bonds with the functionally important 1alpha- and 25-hydroxyl groups of 1alpha,25-dihydroxyvitamin D(3) were identified and confirmed by mutational analysis: the 1alpha-hydroxyl group is forming pincer-type hydrogen bonds with S237 and R274 and the 25-hydroxyl group is interacting with H397. Docking potential for various ligands to the VDR model was examined, and the results are in good agreement with our previous three-dimensional structure-function theory.

Citing Articles

A multidisciplinary approach disclosing unexplored Aflatoxin B1 roles in severe impairment of vitamin D mechanisms of action.

Persico M, Sessa R, Cesaro E, Dini I, Costanzo P, Ritieni A Cell Biol Toxicol. 2022; 39(4):1275-1295.

PMID: 36066700 PMC: 10425525. DOI: 10.1007/s10565-022-09752-y.

Development of In Vitro and In Vivo Evaluation Systems for Vitamin D Derivatives and Their Application to Drug Discovery.

Yasuda K, Nishikawa M, Mano H, Takano M, Kittaka A, Ikushiro S Int J Mol Sci. 2021; 22(21).

PMID: 34769269 PMC: 8584323. DOI: 10.3390/ijms222111839.

A theoretical insight to understand the molecular mechanism of dual target ligand CTA-018 in the chronic kidney disease pathogenesis.

Nagamani S, Muthusamy K PLoS One. 2018; 13(10):e0203194.

PMID: 30286109 PMC: 6171836. DOI: 10.1371/journal.pone.0203194.

The Use of Vitamin D Metabolites and Analogues in the Treatment of Chronic Kidney Disease.

Zand L, Kumar R Endocrinol Metab Clin North Am. 2017; 46(4):983-1007.

PMID: 29080646 PMC: 5977979. DOI: 10.1016/j.ecl.2017.07.008.

Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.

Tebben P, Singh R, Kumar R Endocr Rev. 2016; 37(5):521-547.

PMID: 27588937 PMC: 5045493. DOI: 10.1210/er.2016-1070.

References

Yamada S, Yamamoto K, Masuno H, Ohta M . Conformation-function relationship of vitamin D: conformational analysis predicts potential side-chain structure. J Med Chem. 1998; 41(9):1467-75. DOI: 10.1021/jm970761l. View

Klaholz B, Renaud J, Mitschler A, Zusi C, Chambon P, Gronemeyer H . Conformational adaptation of agonists to the human nuclear receptor RAR gamma. Nat Struct Biol. 1998; 5(3):199-202. DOI: 10.1038/nsb0398-199. View

Williams S, SIGLER P . Atomic structure of progesterone complexed with its receptor. Nature. 1998; 393(6683):392-6. DOI: 10.1038/30775. View

Fagart J, Wurtz J, Souque A, Moras D, Rafestin-Oblin M . Antagonism in the human mineralocorticoid receptor. EMBO J. 1998; 17(12):3317-25. PMC: 1170670. DOI: 10.1093/emboj/17.12.3317. View

Nolte R, Wisely G, Westin S, Cobb J, Lambert M, Kurokawa R . Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 1998; 395(6698):137-43. DOI: 10.1038/25931. View

Sicinski R, Prahl J, Smith C, DeLuca H . New 1alpha,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. J Med Chem. 1998; 41(23):4662-74. DOI: 10.1021/jm9802618. View

Darimont B, Wagner R, Apriletti J, Stallcup M, Kushner P, Baxter J . Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev. 1998; 12(21):3343-56. PMC: 317236. DOI: 10.1101/gad.12.21.3343. View

Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, Berkenstam A . Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma. J Biol Chem. 1998; 273(47):31108-12. DOI: 10.1074/jbc.273.47.31108. View

Vaisanen S, Rouvinen J, Maenpaa P . Putative helices 3 and 5 of the human vitamin D3 receptor are important for the binding of calcitriol. FEBS Lett. 1998; 440(1-2):203-7. DOI: 10.1016/s0014-5793(98)01436-7. View

10.

Shiau A, Barstad D, Loria P, Cheng L, Kushner P, Agard D . The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1999; 95(7):927-37. DOI: 10.1016/s0092-8674(00)81717-1. View

11.

Yamamoto K, Ooizumi H, Umesono K, Verstuyf A, Bouillon R, DeLuca H . Three-dimensional structure-function relationship of vitamin D: side chain location and various activities. Bioorg Med Chem Lett. 1999; 9(7):1041-6. DOI: 10.1016/s0960-894x(99)00129-8. View

12.

Norman A, Adams D, Collins E, Okamura W, Fletterick R . Three-dimensional model of the ligand binding domain of the nuclear receptor for 1alpha,25-dihydroxy-vitamin D(3). J Cell Biochem. 1999; 74(3):323-33. View

13.

Munson P, Rodbard D . Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980; 107(1):220-39. DOI: 10.1016/0003-2697(80)90515-1. View

14.

Evans R . The steroid and thyroid hormone receptor superfamily. Science. 1988; 240(4854):889-95. PMC: 6159881. DOI: 10.1126/science.3283939. View

15.

Umesono K, Murakami K, Thompson C, Evans R . Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell. 1991; 65(7):1255-66. PMC: 6159884. DOI: 10.1016/0092-8674(91)90020-y. View

16.

Laudet V, Hanni C, Coll J, Catzeflis F, Stehelin D . Evolution of the nuclear receptor gene superfamily. EMBO J. 1992; 11(3):1003-13. PMC: 556541. DOI: 10.1002/j.1460-2075.1992.tb05139.x. View

17.

Kristjansson K, Rut A, Hewison M, ORIORDAN J, Hughes M . Two mutations in the hormone binding domain of the vitamin D receptor cause tissue resistance to 1,25 dihydroxyvitamin D3. J Clin Invest. 1993; 92(1):12-6. PMC: 293517. DOI: 10.1172/JCI116539. View

18.

Bouillon R, Sarandeses L, Allewaert K, Zhao J, Mascarenas J, Mourino A . Biologic activity of dihydroxylated 19-nor-(pre)vitamin D3. J Bone Miner Res. 1993; 8(8):1009-15. DOI: 10.1002/jbmr.5650080815. View

19.

Nakajima S, Hsieh J, MacDonald P, Galligan M, Haussler C, Whitfield G . The C-terminal region of the vitamin D receptor is essential to form a complex with a receptor auxiliary factor required for high affinity binding to the vitamin D-responsive element. Mol Endocrinol. 1994; 8(2):159-72. DOI: 10.1210/mend.8.2.8170472. View

20.

Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D . Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature. 1995; 375(6530):377-82. DOI: 10.1038/375377a0. View